QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

RGNX

QT60REGENXBIO Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
7.80
-0.10-1.27%
OverviewShort InterestFilings
RGNXQT60REGENXBIO Inc.·NASDAQ
OverviewShort InterestFilings
7.80-1.27%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-5.60
Insider Own8.91%
Shs Outstand51.70M
Perf Week24.20%
Market Cap408.41MForward P/E-EPS next Y-3.02Insider Trans0.83%Shs Float-Perf Month37.81%
Enterprise Value464.25MPEG0.02EPS next Q0.12Inst Own-Short Float-Perf Quarter-6.70%
Income-285969410.00P/S4.65EPS this Y48.44%Inst Trans-Short Ratio-Perf Half Y-44.72%
Sales87.82MP/B19.65EPS next Y-4.63%ROA-84.83%Short Interest-Perf YTD-45.83%
Book/sh0.41P/C-EPS next 5Y-ROE-232.50%52W High16.19 -51.82%Perf Year-9.93%
Cash/sh2.90P/FCF-EPS past 3/5Y-ROIC-92.12%52W Low5.46 42.86%Perf 3Y-
Dividend Est.-EV/EBITDA-2.02Sales past 3/5Y14.58% 1.86%Gross Margin-0.14%Volatility7.52% 5.57%Perf 5Y-
Dividend TTM-EV/Sales5.29EPS Y/Y TTM-22.00%Oper. Margin-292.28%ATR (14)0.65Perf 10Y-
Dividend Ex-Date-Quick Ratio2.62Sales Y/Y TTM4.82%Profit Margin-330.23%RSI (14)56.89Recom2.20
Dividend Gr. 3/5Y-Current Ratio2.62EPS Q/Q-1533.33%SMA2015.94%Beta2.21Target Price22.86
Payout0.00%Debt/Eq3.37Sales Q/Q-93.26%SMA50-1.90%Rel Volume2.08Prev Close7.90
Employees353LT Debt/Eq2.06EarningsAug 06SMA200-24.56%Avg Volume1.50MPrice7.80
IPO DateSep 17, 2015Option/ShortYes / YesEPS/Sales Surpr.-26.47% -76.92%Net Debt/EBITDA-0.24Volume3,114,529Change-1.27%
Analyst Ratings
DateActionAnalystRatingTarget
May-15-26ReiteratedMorgan StanleyOverweight$17 → $16
May-15-26ReiteratedBarclaysOverweight$37 → $12
Mar-09-26ReiteratedH.C. Wainwright$32 → $30
Feb-10-26ReiteratedH.C. Wainwright$34 → $32
Feb-10-26ReiteratedRobert W. Baird$39 → $27
Feb-10-26ReiteratedUBSBuy$25 → $18
Feb-10-26ReiteratedGoldman SachsNeutral$38 → $12
Jan-29-26ReiteratedH.C. Wainwright$39 → $34
Jan-27-26ReiteratedBarclaysOverweight$37
Dec-19-25ReiteratedStifel Nicolaus$40 → $45
Latest News
Jun-18-26
Jun-18-2603:28PM
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study InitiationsSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue8717083
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A882034
Gross Profit-115050
Selling, General and Administrative Excl. Other838377
Research and Development229228209
Other Operating Expense-550-3
Operating Income-256-161-233
Interest Expense454513
Unusual Expense
———
Non-Operating Income (Expense)-12-12-19
Net Income Before Taxes-290-194-227
Income Taxes000
Consolidated Net Income-290-194-227
Net Income From Continuing Operations-290-194-227
Net Income-290-194-227
EPS (Recurring)-5.60-3.76-4.59
EPS (Basic, Before Extraordinaries)-5.60-3.76-4.59
EPS (Diluted)-5.60-3.76-4.59
EBITDA-229-133-198
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio4.664.40—
Gross Margin-1.1588.2460.24
Operating Margin-294.25-94.71-280.72
Net Margin-333.33-114.12-273.49
Shares Outstanding525250
Market Capitalization406749—
Operating Lease Expense
———
Insider Trading Volume
$8.16$7.37$6.59$5.80$5.01● Close Price0.00K65.66K131.32K196.98K262.63KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
PAKOLA STEVEChief Medical OfficerMay 11 '26Sale11.0215,309168,705232,617May 13 12:00 AM
PAKOLA STEVEChief Medical OfficerMar 10 '26Sale10.355,12453,033247,926Mar 12 12:00 AM
Mills Kenneth T.DirectorJan 27 '26Option Exercise13.09450,0005,890,500707,871Jan 29 12:00 AM
Simpson CurranChief Executive OfficerOct 09 '25Sale12.6220,811262,635216,162Oct 10 12:00 AM
Simpson CurranChief Executive OfficerSep 29 '25Sale10.037,62476,469236,973Oct 01 12:00 AM
Simpson CurranChief Executive OfficerSep 10 '25Sale10.027,73477,495244,597Sep 12 12:00 AM
Mills Kenneth T.DirectorMay 12 '25Option Exercise3.7641,204154,928495,705May 14 12:00 AM
Mills Kenneth T.DirectorMay 12 '25Sale7.9120,602163,046475,103May 14 12:00 AM
Mills Kenneth T.DirectorMar 27 '25Option Exercise3.7661,504231,256475,103Mar 31 12:00 AM
KARABELAS ARGERIS NDirectorOct 01 '24Option Exercise3.7620,00075,20021,286Oct 02 12:00 AM
KARABELAS ARGERIS NDirectorOct 01 '24Sale10.1110,000101,05211,286Oct 02 12:00 AM
KARABELAS ARGERIS NDirectorSep 03 '24Option Exercise3.7620,00075,20021,286Sep 04 12:00 AM
KARABELAS ARGERIS NDirectorSep 03 '24Sale11.5610,000115,58811,286Sep 04 12:00 AM
Mills Kenneth T.DirectorAug 08 '24Option Exercise0.8572,63261,738444,351Aug 12 12:00 AM
KARABELAS ARGERIS NDirectorAug 01 '24Option Exercise3.8520,20077,74821,386Aug 05 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR